Рациональная фармакотерапия метаболических факторов риска эректильной дисфункции

Рациональная фармакотерапия метаболических факторов риска эректильной дисфункции

Автор: Красняк Степан Сергеевич

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Андрология

Статья в выпуске: 4 т.15, 2022 года.

Бесплатный доступ

Актуальность. Процесс достижения эрекции происходит за счет координации нескольких путей. Поэтому любые негативные состояния и факторы риска будут ухудшать качество эрекции и могут вызвать эректильную дисфункцию (ЭД). Одним из таких состояний является метаболический синдром. Цель. Изучить опубликованные за последние 20 лет данные по распространению, причинам и факторам риска, а также консервативной терапии ЭД. Материалы и методы. Были проанализированы результаты поиска в научной базе данных PubMed по запросам «физиология эрекции», «эректильная дисфункция», «факторы риска эректильной дисфункции», «лечение эректильной дисфункции». Найдено 574 работ, отобрано для написания обзора 60 статей. Результаты. Глобальная распространенность ЭД сильно колеблется и составляет от 3 до 76,5%, при этом, ЭД связана с возрастом. Одними из основных факторов риска ЭД являются артериальная гипертензия, ожирение, гиперлипидемия и сахарный диабет. На сегодняшний момент консервативная терапия ЭД направлена на лечение отдельных факторов риска и зачастую не способна оказывать комплексное действие на все факторы сразу, что приводит к необходимости комбинировать медикаменты. Заключение. Так как консервативная терапия ЭД не может быть направлена на все этиологические стороны данной патологии одновременно, необходимо применение комбинированного средства метаболической терапии ЭД, которое устраняет основные причины развития эректильной дисфункции, и защищает эндотелиальные клетки кавернозных тел.

Еще

Эректильная дисфункция, факторы риска, лечение, хрома пиколинат, экстракт чеснока, псиллиум, экстракт шалфея

Короткий адрес: https://sciup.org/142236663

IDR: 142236663   |   DOI: 10.29188/2222-8543-2022-15-4-86-94

Список литературы Рациональная фармакотерапия метаболических факторов риска эректильной дисфункции

  • McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 2016;13(2):144-52. https://doi.org/10.1016/j.jsxm.2015.12.019.
  • Nguyen HMT, Gabrielson AT, Hellstrom WJG. Erectile dysfunction in young men—a review of the prevalence and risk factors. Sex Med Rev 2017;5(4):508-20. https://doi.org/10.1016/j.sxmr.2017.05.004.
  • Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112(17):2735-52. https://doi.org/10.1161/ CIRCULATI0NAHA.105.169404.
  • Kessler A, Sollie S, Challacombe B, Briggs K, Van Hemelrijck M. The global prevalence of erectile dysfunction: a review. BJU Int 2019;124(4): 587-99. https://doi.org/10.1111/bju.14813.
  • Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151(1):54-61. https://doi.org/10.1016/S0022-5347(17)34871-1.
  • Wong SY, Leung JC, Woo J. Sexual activity, erectile dysfunction and their correlates among 1,566 older Chinese men in Southern China. J Sex Med 2009;6(1):74-80. https://doi.org/10.1111/j.1743-6109.2008.01034.x.
  • Zhang X, Yang B, Li N, Li H. Prevalence and risk factors for erectile dysfunction in chinese adult males. J Sex Med 2017;14(10):1201-8. https://doi.org/10.1016/j.jsxm.2017.08.009.
  • Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, Paick JS, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 2010;7(1 Pt 2):445-75. https://doi.org/10.1111/ j.1743-6109.2009.01624.x.
  • Martínez-Salamanca JI, Martínez-Ballesteros C, Portillo L, Gabancho S, Moneada I, Carballido J. Physiology of erection. Arch Esp Urol 2010;63(8):581-8.
  • Udelson D. Biomechanics of male erectile function. J R Soc Interface 2007;4(17):1031-47, https://doi.org/10.1098/rsif.2007.0221.
  • Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005;32(4):379-95. https://doi.org/10.1016/j.ucl.2005.08.007.
  • Bosch RJ, Benard F, Aboseif SR, Stief CG, Lue TF, Tanagho EA. Penile detumescence: characterization of three phases. J Urol 1991;146(3):867-71. https://doi.org/10.1016/S0022-5347 (17)37950-8.
  • Dail WG, Trujillo D, de la Rosa D, Walton G. Autonomic innervation of reproductive organs: Analysis of the neurons whose axons project in the main penile nerve in the pelvic plexus of the rat. Anat Rec 1989;224(1):94-101. https://doi.org/10.1002/ar.1092240112.
  • Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Bachem Biophys Res Commun 1990;170(2):843-50. https://doi.org/10.1016/0006-291X(90)92168-Y.
  • Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A, et al. EAU Guidelines on «Sexual and Reproductive Health» European Association of Urology 2022. URL: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2022_2022-03-29-084141_megw.pdf.
  • Li HJ, Kang DY. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: a meta-analysis. World J Urol 2016;34(7):1009-17. https://doi.org/10.1007/ s00345-015-1720-3.
  • Corona G, Rastrelli G, Limoncin E, Sforza A, Jannini EA, Maggi M. Interplay between premature ejaculation and erectile dysfunction: a systematic review and meta-analysis. J Sex Med 2015;12(12):2291-300. https://doi.org/10.1111/jsm.13041.
  • Feng C, Xu YM, Barbagli G, Lazzeri M, Tang CY, Fu Q, Sa YL. The relationship between erectile dysfunction and open urethroplasty: a systematic review and meta-analysis. J Sex Med 2013;10(8):2060-8. https://doi.org/10.1111/jsm.12181.
  • Karakulak NU, Okutucu S, Lokman U, Bilgin O, Tutkun E, Hinc Yilmaz O, Oto A. Evaluation of erectile dysfunction and left ventricular diastolic parameters in lead exposed workers. Acta Cardiol Sin 2019;35(1):75-84. https://doi.org/10.6515/ACS.201901_35(1).20180716A
  • Selvin E, Burnett AL, Platz EA. Prevalence and Risk Factors for Erectile Dysfunction in the US. Am J Med 2007;120(2):151-7. https://doi.org/10.1016/j.amjmed.2006.06.010.
  • Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34(28):2159-219. https://doi.org/10.1093/eurheartj/eht151.
  • Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular risk: The EVA syndrome. J Hypertens 2008;26(6):1049-57. https://doi.org/10.1097/HJH.0b013e3282f82c3e.
  • Kaya E, Sikka SC, Gur S. A Comprehensive review of metabolic syndrome affecting erectile dysfunction. J Sex Med 2015;12(4):856-75. https://doi.org/10.1111/jsm.12828.
  • Moon KH, Park SY, Kim YW. Obesity and erectile dysfunction: From bench to clinical implication. World J Mens Health 2019;37(2):138-47. https://doi.org/10.5534/wjmh.180026.
  • Ghosh A, Gao L, Thakur A, Siu PM, Lai CWK. Role of free fatty acids in endothelial dysfunction. Biomed Sci 2017;24(1):50. https://doi.org/10.1186/s12929-017-0357-5.
  • Gonzalez-Cadavid NF, Rajfer J. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction. Exp Gerontol 200439(11-12):1705-12. https://doi.org/10.1016/j.exger.2004.06.022.
  • Roumeguere T, Wespes E, Carpentier Y, Hoffmann P, Schulman CC. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003;44(3):355-9. https://doi.org/10.1016/S0302-2838(03)00306-3.
  • Mitidieri E, Cirino G, d'Emmanuele di Villa Bianca R, Sorrentino R. Pharmacology and perspectives in erectile dysfunction in man. Pharmacol Ther 2020;208:107493. https://doi.org/10.1016/ j.pharmthera.2020.107493.
  • Binmoammar TA, Hassounah S, Alsaad S, Rawaf S, Majeed A. The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: a systematic review. JRSM Open 2016;7(3):205427041562260. https://doi.org/10.1177/2054270415622602.
  • Wessells H, Penson DF, Cleary P, Rutledge BN, Lachin JM, McVary KT, et al. Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol 2011;185(5):1828-34. https://doi.org/10.1016/j.juro.2010.12.098.
  • Общий алгоритм лечения артериальной гипертензии. https://dommedika.com/cardiol-ogy/algoritm_lechenia_gipertenzii.html.
  • Foster G. The behavioral approach to treating obesity. Am Heart J 2006;151(3):625-7. https://doi.org/10.1016/j.ahj.2005.03.003.
  • Aggarwal BB, Gupta SC, Sung B. Curcumin: An orally bioavailable blocker of TNF and other proinflammatory biomarkers. Br J Pharmacol 2013;169(8):1672-92. https://doi.org/10.1111/bph.12131.
  • Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-934. https://doi.org/10.10167j.jacc.2013.11.002.
  • Karr S. Epidemiology and Management of Hyperlipidemia. Am J Manag Care 2017;23(9 Suppl):S139-S148 .
  • Лекарства от диабета - виды, эффекты, побочные эффекты (таблица). Университетская клиника. URL: https://unclinic.ru/lekarstva-ot-diabeta-vidy-jeffekty-pobochnye-jeffekty-tablica/
  • Инсулины: описание фармакологической группы в Энциклопедии РЛС. URL: https://www.rlsnet.ru/pharm-groups/insuliny-100.
  • Rashid A, Khan HH. The mechanism of hypotensive effect of garlic extract. J Pak Med Assoc 1985;35(12):357-62.
  • Shang A, Cao SY, Xu XY, Gan RY, Tang GY, Corke H, et sl. Bioactive compounds and biological functions of garlic (Allium sativum L.). Foods 2019;8(7):246. https://doi.org/10.3390/foods8070246.
  • Liperoti R, Vetrano DL, Bernabei R, Onder G. Herbal Medications in Cardiovascular Medicine. J Am Coll Cardiol 2017;69(9):1188-99. https://doi.Org/10.1016/j.jacc.2016.11.078.
  • Chan JY, Yuen AC, Chan RY, Chan SW. A review of the cardiovascular benefits and antioxidant properties of allicin. Phytotherapy Res 2013;27(5):637-46 https://doi.org/10.1002/ptr.4796.
  • Sial AY, Ahmad SJ. Study of the hypotensive action of garlic extract experimental animals. Pages with reference to book, from 237 to 239. URL: https://jpma.org.pk/PdfDownload/6567
  • Banerjee SK, Maulik SK. Effect of garlic on cardiovascular disorders: a review. Nutr J 2002;1(1):4. https://doi.org/10.1186/1475-2891-1-4.
  • Omar SH. Garlic and cardiovascular diseases. In book Natural Products: Phytochemistry, Botany and Metabolism of Alkaloids, Phenolics and Terpene. Ed. K.G. Ramawat, J.M. Merillon. Springer Berlin Heidelberg 2013:3661-6 p.
  • Auer W, Eiber A, Hertkorn E, Hoehfeld E, Koehrle U, Lorenz A, et al. Hypertension and hy-perlipidaemia: garlic helps in mild cases. Br J Clin Pract 1990;69:3-6.
  • Kandziora J. Blutdruck- und lipidsenkendeWirkung eines knoblauch-preparates in kombination mit einem diuretikum. Aerztliche Forsch 1988;35:3-8.
  • Stabler SN, Tejani AM, Huynh F, Fowkes C. Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients. Cochrane Database Syst Rev 2012;2012(8):CD007653. https://doi.org/10.1002/14651858.cd007653.pub2.
  • Ried K, Frank OR, Stocks NP. Aged garlic extract reduces blood pressure in hypertensives: A dose-response trial. Eur J Clin Nutr 2013;67(1):64-70. https://doi.org/10.1038/ejcn.2012.178.
  • Kamanna VS, Chandrasekhara N. Effect of garlic (Allium sativum linn) on serum lipoproteins and lipoprotein cholesterol levels in albino rats rendered hypercholesteremic by feeding cholesterol. Lipids 1982;17(7):483-8. https://doi.org/10.1007/BF02535329.
  • Rahman K, Lowe GM. Garlic and cardiovascular disease: A critical review. J Nutr 2006;136(3 Suppl):736S-740S. https://doi.org/10.1093/jn/136.3J36s.
  • Jain RC. Effect of garlic on serum lipids, coagulability and fibrinolytic activity of blood. Am J Clin Nutr 1977;30(9):1380-1. https://doi.org/10.1093/ajcn/30.9.1380.
  • Gardner CD, Chatterjee LM, Carlson JJ. The effect of a garlic preparation on plasma lipid levels in moderately hypercholesterolemic adults. Atherosclerosis 2001;154(1):213-20. https://doi.org/10.1016/S0021-9150(00)00466-4.
  • Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: An updated meta-analysis. Nutr Rev 2013;71(5):282-99. https://doi.org/10.1111/nure.12012.
  • Ota A, Ulrih NP. An overview of herbal products and secondary metabolites used for management of type two diabetes. Front Pharmacol 2017;8:436. https://doi.org/10.3389/fphar.2017.00436.
  • Jeejeebhoy K, Chu R, Marliss E, Greenberg G, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977;30:531-8.
  • Lewicki S, Zdanowski R, Krzyzowska M, Lewicka A, D^bski B, Niemcewicz M, et al. The role of chromium III in the organism and its possible use in diabetes and obesity treatment. Ann Agric Environ Med 2014;21(2):331-5. https://doi.org/10.5604/1232-1966.1108599.
  • Wiernsperger N, Rapin J. Trace elements in glucometabolic disorders: an update. Diabetol Metab Syndr 2010;2:70. https://doi.org/10.1186/1758-5996-2-70.
  • San Mauro-Martin I, Ruiz-León AM, Camina-Martín MA, Garicano-Vilar E, Collado-Yurrita L, Mateo-Silleras Bd, et al. Chromium supplementation in patients with type 2 diabetes and high risk of type 2 diabetes: A meta-analysis of randomized controlled trials. Nutr Hosp 2016;33(1):27. https://doi.org/10.20960/nh.27.
  • Suksomboon N, Poolsup N, Yuwanakorn A. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther 2014;39(3):292-306. https://doi.org/10.1111/jcpt.12147.
  • Lambeau KV, McRorie JW. Fiber supplements and clinically proven health benefits: how to recognize and recommend an effective fiber therapy. J Am Assoc Nurse Pract 2017;29(4):216-23. https://doi.org/10.1002/2327-6924.12447.
  • Cicero AFG, Derosa G, Bove M, Imola F, Borghi C, Gaddi AV. Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. Med J Nutrition Metab 2010;3(21):47-54. https://doi.org/10.1007/s12349-009-0056-1.
  • Chen L, Guo Q-H, Chang Y, Zhao Y-S, Li A-Y, Ji E-S. Tanshinone IIA ameliorated endothelial dysfunction in rats with chronic intermittent hypoxia. Cardiovasc Pathol 2017;31:47-53. https://doi.org/10.1016/jcarpath.2017.06.008.
  • Zhang Y, Chen J, Ji H, Xiao ZG, Shen P, Xu LH. Protective effects of Danshen injection against erectile dysfunction via suppression of endoplasmic reticulum stress activation in a streptozotocin-induced diabetic rat model. BMC Complement Altern Med 2018;18(1):343. https://doi.org/10.1186/ s12906-018-2414-3.
Еще
Статья обзорная
SciUp 2024 © 2024 ©